Oncotelic Therapeutics, Inc.
OTLC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OTLC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OTLC
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing RNA therapeutics, primarily OT-101, for cancer and other diseases, with a history of losses and substantial doubt about its ability to continue as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Market Cap
$13.7M
Cash Runway
—
Lead Asset
al-101
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates for Oncotelic Therapeutics, Inc..
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing RNA therapeutics, primarily OT-101, for cancer and other diseases, with a history of losses and substantial doubt about its ability to continue as a going concern.
- Oncotelic is a clinical-stage biopharmaceutical company developing drugs for cancer, with lead candidate OT-101 targeting TGF-β overexpression [sec_mda · as of 2025-11-17].
- The company reported total revenue of $0.2M and net income of $0.4M for the period ending 2026-06-30, with shareholders' equity of $262.8M and total debt of $1.9M [sec].
- The company has a history of recurring losses and its auditors have expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-14].
- Oncotelic has formed a joint venture (JV) with Dragon to shift development costs and reduce direct expenses, but still requires additional capital to fund operations [sec_mda · as of 2025-11-17].
What works
- OT-101 has shown promising clinical activity in phase 2 trials for gliomas and pancreatic cancers [sec_mda · as of 2025-11-17].
- The company has a broad pipeline including AL-101, OXi4503, CA4P, and apomorphine, targeting multiple therapeutic areas [sec_mda · as of 2025-08-13].
- The JV with Dragon has shifted substantial development and G&A costs away from Oncotelic, reducing its direct capital requirements [sec_mda · as of 2025-11-17].
What to weigh
- The company has a history of recurring losses and substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-14].
- Oncotelic's limited capital resources and need to raise additional funds may force it to delay, scale back, or eliminate development programs [sec_mda · as of 2026-04-15].
- The company has no new financing arrangements in place beyond existing agreements, and any equity financing would be dilutive to current shareholders [sec_mda · as of 2025-04-15].
From the filings
Quoted directly from source documents.
The company has substantial doubt about its ability to continue as a going concern.
“The Company's limited capital resources, history of recurring losses and uncertainties as to whether the Company's operations will become profitable raise substantial doubt about its ability to continue as a going concern.”
SEC MD&A · May 14, 2026
OT-101 has shown promising clinical activity in phase 2 trials.
“The Company's proprietary product candidates have shown promising clinical activity in phase 2 trials for the treatment of gliomas and pancreatic cancers.”
SEC MD&A · November 17, 2025
The company needs to raise additional capital to continue development.
“If the Company is unable to access additional funds when needed, it may not be able to continue the development of these investigational drugs and the Company could be required to delay, scale back or eliminate some or all of its development program”
SEC MD&A · April 15, 2026
The JV with Dragon has reduced the company's direct expenses.
“Since the Company formed the JV with Dragon, all costs associated with developing the assets licensed to the JV and a substantial portion of the Company's general and administrative expenses have shifted to the JV reducing the Company's direct expenses and capital requirements.”
SEC MD&A · November 17, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Auditors have raised substantial doubt about the company's ability to continue as a going concern due to limited capital and recurring losses [sec_mda · as of 2026-05-14].
- Need for additional capital — The company requires additional funds to continue operations and development; no new financing arrangements are in place [sec_mda · as of 2026-04-15].
- Dependence on JV structure — The company's reduced expenses rely on the JV with Dragon; any disruption could increase direct costs [sec_mda · as of 2025-11-17].
- Dilution from equity financing — Any future equity financing would be dilutive to existing shareholders [sec_mda · as of 2025-04-15].
What to watch
- Ability to secure new financing or partnerships to fund ongoing development and address going concern [sec_mda · as of 2026-04-15].
- Progress of OT-101 in clinical trials for gliomas and pancreatic cancers [sec_mda · as of 2025-11-17].
- Updates on the JV with Dragon and its impact on cost structure and pipeline development [sec_mda · as of 2025-11-17].
- Regulatory or clinical milestones for other pipeline candidates such as OXi4503 and CA4P [sec_mda · as of 2025-08-13].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Oncotelic Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oncotelic Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.50 · 5% dilution
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
7 buys · 0 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Jun 2021Institutional holders
1
Total value held
$12K
| Holder | Shares | Value |
|---|---|---|
| ifp advisors, inc | 61,196 | $12K |
Short Interest
as of May 22, 2026- % of float
- 2.5%
- Days to cover
- 8.0
- Shares short
- 662,753
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OTLC short interestFrequently asked questions
What is the AI investment thesis for Oncotelic Therapeutics, Inc.?
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing RNA therapeutics, primarily OT-101, for cancer and other diseases, with a history of losses and substantial doubt about its ability to continue as a going concern.
Who is the CEO of Oncotelic Therapeutics, Inc.?
Dr. Vuong Trieu Ph.D. is the chief executive officer of Oncotelic Therapeutics, Inc. (OTLC).
Where is Oncotelic Therapeutics, Inc. headquartered?
Oncotelic Therapeutics, Inc. (OTLC) is headquartered in Agoura Hills, CA, United States.
What therapeutic areas does Oncotelic Therapeutics, Inc. focus on?
Oncotelic Therapeutics, Inc. develops therapies across Oncology, Neurology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.